CP1 device for Myopia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Manhattan Vision Associates/Institute of Vision Research, New York, NY
Myopia
Binocular CP1 - Device
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

Kubota Vision Inc. has developed a spectacle-like prototype device which is designed to be used as a light-based therapy to reduce myopia progression. In this study, we aim to observe the ocular biometric and refractive changes following binocular part-time wear of the clinical prototype device over a course of 12 months and compare that to 12 months of no clinical prototype device use (control).

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
Central axial length
Cycloplegic refraction

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control
1 of 2
CP1 device
1 of 2
Active Control

45 Total Participants · 2 Treatment Groups

Primary Treatment: CP1 device · No Placebo Group · N/A

ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
CP1 device
Device
ActiveComparator Group · 1 Intervention: Binocular CP1 · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: Manhattan Vision Associates/Institute of Vision Research · New York, NY
Photo of New York  1Photo of New York  2Photo of New York  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Myopia
0 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The sphere of vision is less than -5.50 diopters.
You have a visual acuity of at least 20/25 in each eye.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.